The role of SMARCA5 in cancer appears to be tissue type-specific, as the expression of SMARCA5 is upregulated in cervical and prostate cancers, whereas downregulation is reported in multiple myeloma, HCC, gastric cancer, intrahepatic cholangiocarcinoma, and non-small cell lung cancer (Figure 6) [97,98,99,100]. This evidence concerns the gene SMARCA5 and prostate cancer.